,i  #aafth ,,congress  #ast ,session    
,h4 ,r4 #ddjd  ,,in ,,the ,,house ,,of  
,,representatives  ,september #ai1      
#bjai,mr4 ,rush introduced the following
 bill2 which was referred to the        
,committee on ,energy and ,commerce  ,a 
,,bill  ,to amend the ,federal ,food1   
,drug1 and ,cosmetic ,act to require    
that the label of drugs with an         
increased risk of suicide or depression 
present such increased risk prominently1
 and for other purposes4  #a4 ,short    
title ,this ,act may be cited as the    
,depression ,side ,effect ,labeling     
,awareness ,act of #bjai4  #b4          
,prominent drug labeling for increased  
risk of suicide or depression  7a7 ,in  
general ,section #ejb of the ,federal   
,food1 ,drug1 and ,cosmetic ,act 7#ba   
,u4,s4,c4 #ceb7 is amended by adding at 
the end the following3  7ee7 ,if the    
warnings and precautions in the drug's  
label include an increased risk of      
suicide or depression1 unless such      
increased risk is presented prominently4

  4  7b7 ,regulations ,not later than #a
 year after the date of enactment of    
this ,act1 the ,secretary of ,health and
 ,human ,services1 acting through the   
,commissioner of ,food and ,drugs1 shall
 promulgate final regulations to carry  
out section #ejb7;ee7 of the ,federal   
,food1 ,drug1 and ,cosmetic ,act1 as    
added by subsection 7a74 ,before        
promulgating such regulations1 the      
,secretary shall consult with           
stakeholders1 including manufacturers of
 drugs4  7c7 ,delayed applicability     
,such section #ejb7;ee7 shall not apply 
until the ,secretary of ,health and     
,human ,services has issued a final     
regulation under subsection 7b74